A Window-of-opportunity Trial Reveals Mechanisms of Response and Resistance to Navtemadlin in Patients with Recurrent Glioblastoma.
Veronica Rendo,Eudocia Q Lee, Connor Bossi,Nicholas Khuu,Michelle A Rudek,Sangita Pal,Narmen Azazmeh,Rumana Rashid,Jia-Ren Lin, Margaret Cusick, Abigail R N Reynolds, Auriole C R Fassinou, Georges Ayoub, Seth Malinowski,Emily Lapinskas, William Pisano, John Jeang, Sylwia A Stopka, Michael S Regan,Johan Spetz,Arati Desai,Frank Lieberman, Kamalakannan Palanichamy, Joy D Fisher,Kristine Pelton,Raymond Y Huang,Kristopher A Sarosiek, Louis B Nabors,Matthias Holdhoff, Neeraja Danda,Roy Strowd, Serena Desideri,Tobias Walbert,Xiaobu Ye,Arnab Chakravarti,Peter K Sorger,Sandro Santagata, Nathalie Y R Agar,Stuart A Grossman,Brian M Alexander,Patrick Y Wen,Keith L Ligon,Rameen Beroukhim Science translational medicine（2025）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper